Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Naïve and newly debuted: configurations of the trial participant in phase II-III clinical trials
Luleå University of Technology, Department of Business Administration, Technology and Social Sciences, Human Work Science.
2008 (English)In: Society for Social Studies of Science, European Association for the Study of Science and Technology , 2008Conference paper, Meeting abstract (Other academic)
Abstract [en]

An increasingly large part of pharmaceutical testing is performed by contract research organisations (CROs). This development is a consequence of the pharmaceutical industry's need to speed up the trial process in order to get drugs out to the market quicker, as well as a result of tighter bureaucracy surrounding clinical trials. Tasks performed by CROs include faster screening and recruitment of test subjects, tasks that traditionally have been done by the clinics themselves. For Sweden and other European countries, such a change implies large scale privatisation of the work performed in clinical trials. This paper discusses the consequences of this privatisation for the configuration of trial participants.The paper focuses a few of these configurations through analysing the discourses of test subjects in and around contract research organizations as they emerge in one CROs promotional material, as well as in local newspapers' coverage of the company when it was established in a Swedish city in 2004. One of the tasks of the company, dealing with phase II-III trials, is to recruit "naïve" and "newly debuted" participants. This means finding individuals who fit the often narrow inclusion criteria for participating in the trial, but who do not (yet) know that they are "at risk". The multi-layered meanings of this terminology are discussed, and a potential consequence of the argumentation is investigated: a tendency that clinical trials are configured as part of prevention programmes on behalf of public health care practitioners. More broadly, the paper thus focuses how the biomedicalisation of health interrelate with drug testing practice/discourse; and health promotion and prevention initiatives.

Place, publisher, year, edition, pages
European Association for the Study of Science and Technology , 2008.
National Category
Production Engineering, Human Work Science and Ergonomics
Research subject
Gender and Technology
Identifiers
URN: urn:nbn:se:ltu:diva-27539Local ID: 108e1140-a040-11dd-8f4e-000ea68e967bOAI: oai:DiVA.org:ltu-27539DiVA, id: diva2:1000723
Conference
Acting with Science, Technology and Medicine : 20/08/2008 - 23/08/2008
Note
Godkänd; 2008; 20081022 (petjon)Available from: 2016-09-30 Created: 2016-09-30 Last updated: 2017-11-25Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records BETA

Jonvallen, Petra

Search in DiVA

By author/editor
Jonvallen, Petra
By organisation
Human Work Science
Production Engineering, Human Work Science and Ergonomics

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 3 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf